These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 17373584)
1. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Osadchii OE Cardiovasc Drugs Ther; 2007 Jun; 21(3):171-94. PubMed ID: 17373584 [TBL] [Abstract][Full Text] [Related]
2. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Kerfant BG; Zhao D; Lorenzen-Schmidt I; Wilson LS; Cai S; Chen SR; Maurice DH; Backx PH Circ Res; 2007 Aug; 101(4):400-8. PubMed ID: 17615371 [TBL] [Abstract][Full Text] [Related]
3. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457 [TBL] [Abstract][Full Text] [Related]
4. Constitutive phosphodiesterase activity restricts spontaneous beating rate of cardiac pacemaker cells by suppressing local Ca2+ releases. Vinogradova TM; Sirenko S; Lyashkov AE; Younes A; Li Y; Zhu W; Yang D; Ruknudin AM; Spurgeon H; Lakatta EG Circ Res; 2008 Apr; 102(7):761-9. PubMed ID: 18276917 [TBL] [Abstract][Full Text] [Related]
5. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Rao YJ; Xi L Acta Pharmacol Sin; 2009 Jan; 30(1):1-24. PubMed ID: 19060915 [TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats. Kaumann AJ; Galindo-Tovar A; Escudero E; Vargas ML Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):421-30. PubMed ID: 19693491 [TBL] [Abstract][Full Text] [Related]
7. 5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles. Afzal F; Andressen KW; Mørk HK; Aronsen JM; Sjaastad I; Dahl CP; Skomedal T; Levy FO; Osnes JB; Qvigstad E Br J Pharmacol; 2008 Dec; 155(7):1005-14. PubMed ID: 18846035 [TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibition and positive inotropic effects. Schmitz W; von der Leyen H; Meyer W; Neumann J; Scholz H J Cardiovasc Pharmacol; 1989; 14 Suppl 3():S11-4. PubMed ID: 2478797 [TBL] [Abstract][Full Text] [Related]
9. Regulation of murine cardiac function by phosphodiesterases type 3 and 4. Beca S; Aschars-Sobbi R; Panama BK; Backx PH Curr Opin Pharmacol; 2011 Dec; 11(6):714-9. PubMed ID: 22047792 [TBL] [Abstract][Full Text] [Related]
10. Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway. Zhao CY; Greenstein JL; Winslow RL J Mol Cell Cardiol; 2015 Nov; 88():29-38. PubMed ID: 26388264 [TBL] [Abstract][Full Text] [Related]
11. Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation. Osadchii OE; Woodiwiss AJ; Norton GR Pflugers Arch; 2006 May; 452(2):155-63. PubMed ID: 16369769 [TBL] [Abstract][Full Text] [Related]
14. Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4. Vinogradova TM; Sirenko S; Lukyanenko YO; Yang D; Tarasov KV; Lyashkov AE; Varghese NJ; Li Y; Chakir K; Ziman B; Lakatta EG Circ Arrhythm Electrophysiol; 2018 Jun; 11(6):e005896. PubMed ID: 29880528 [TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis. Kyoi T; Oka M; Noda K; Ukai Y Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227 [TBL] [Abstract][Full Text] [Related]
16. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830 [TBL] [Abstract][Full Text] [Related]
17. PDE2 at the crossway between cAMP and cGMP signalling in the heart. Weber S; Zeller M; Guan K; Wunder F; Wagner M; El-Armouche A Cell Signal; 2017 Oct; 38():76-84. PubMed ID: 28668721 [TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure. von der Leyen H Klin Wochenschr; 1989 Jun; 67(12):605-15. PubMed ID: 2671473 [TBL] [Abstract][Full Text] [Related]
19. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. Johnson WB; Katugampola S; Able S; Napier C; Harding SE Life Sci; 2012 Feb; 90(9-10):328-36. PubMed ID: 22261303 [TBL] [Abstract][Full Text] [Related]
20. Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes. Mika D; Bobin P; Pomérance M; Lechêne P; Westenbroek RE; Catterall WA; Vandecasteele G; Leroy J; Fischmeister R Cardiovasc Res; 2013 Nov; 100(2):336-46. PubMed ID: 23933582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]